Branch atheromatous disease (BAD)
Conditions
Interventions
Control group:Standard treatment
Alirocumab group:Treatment with alixirumab
Sponsors
Ganzhou people's hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age>=18 years; 2. Patients who meet diagnostic criteria for BAD: (1) First meet the diagnostic criteria for acute ischemic stroke; (2) Ischemic stroke in the lenticular artery region: DWI showed that the infarct lesions in the corresponding blood supply area involved 3 or more levels in the horizontal position; The lenticular artery supply areas are: most of the putamen nucleus, the lateral part of the globus pallidus, the head and body of the caudate nucleus, the forelimbs of the internal capsule, the upper part of the internal capsule, and the radial crown around the ventricles; (3) Ischemic stroke in the parapontine median artery region: DWI showed that the infarct was connected to the brain surface on the ventral side of the pont, and the lesion was close to the midline, located on one side and not exceeding the midline; 3. NIHSS score of 3-8 points; 4. mRS<=1 point before onset; 5. Patients and their families voluntarily participate in the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Comorrhage or other pathological brain disorders such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis) based on baseline head CT or MRI examinations; 2. CTA or DSA examination shows the stenosis of the responsible large vessel >=70%; 3. DWI showed cortical infarction, watershed infarction and multiple cerebral infarctions; 4. Cerebral infarction caused by other causes, such as cardiogenic cerebral embolism, immune or infectious vasculitis, abnormal coagulation function and other reasons (such as vasculitis, shock, antiphospholipid antibody syndrome, etc.); 5. History of cirrhosis, chronic active hepatitis, or severe liver disease; 6. Hepatic insufficiency or renal insufficiency (hepatic insufficiency is defined as ALT value > 2 times the upper limit of normal or AST value > 2 times the upper limit of normal; Renal insufficiency is defined as serum creatinine > 1.5 times the upper limit of normal or glomerular filtration eGFR <50ml/min); 7. Have severe non-cardiovascular and cerebrovascular disease with an expected survival time of less than 90 days; 8. Inability to understand or obey the study due to mental disorders, cognitive or emotional disorders, etc., which the investigator considers inappropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence rate of END within 7 days; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of ischemic stroke at day 30 and 90;The incidence of TIA at day 30 and 90;The incidence of unfavorable functional outcomes (mRS score >1) at day 30 and 90;The LDL-C levels on day 7 and 30;Adverse events within 30 days;Serious adverse events within 30 days;An increase in creatine kinase or abnormal liver function within 30 days;The rate of improvement within 7 days or 14 days; | — |
Countries
China
Contacts
Public ContactXianghong Liu
Ganzhou people's hospital
Outcome results
None listed